10-K: Annexon's 10-K Filing: GBS Program Nears BLA Submission, GA Trial Progresses

Annexon's 10-K filing highlights progress in its GBS program with a planned BLA submission in early 2025 and the advancement of its GA trial, while reporting a net loss of $138.2 million for 2024.

Summary

• Annexon, a clinical-stage biopharmaceutical company, is focused on developing complement medicines for inflammatory-related diseases.
• The company's lead candidate, ANX005, is being developed as a potential treatment for Guillain-Barr Syndrome (GBS), with a Phase 3 trial showing significant improvement in patients.
• Annexon anticipates a pre-BLA meeting with the FDA in the first half of 2025, targeting a BLA submission thereafter.
• ANX007, another key candidate, is in Phase 3 development for Geographic Atrophy (GA), with topline data expected in the second half of 2026.
• A Phase 3 trial, ARCHER II, is underway, enrolling approximately 630 patients with dry AMD with GA.
• ANX1502, an oral small molecule inhibitor, is being evaluated in a proof-of-concept study for cold agglutinin disease (CAD), with data expected in mid-2025.
• The company reported a net loss of $138.2 million for the year ended December 31, 2024, and had cash and investments of $312.0 million.
• Annexon expects its current capital resources to fund operations into the second half of 2026.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. Positive clinical trial results and advancement of key programs are offset by significant net losses and the need for future financing. The company's ability to execute its strategy and navigate the competitive landscape will be crucial.

Positives

• Positive Phase 3 trial results for ANX005 in GBS, supporting a potential BLA submission.
• RWE study reinforces the benefits of ANX005 over standard of care in GBS.
• ARCHER II trial initiation for ANX007 in GA, with a streamlined single-study program.
• PRIME designation for ANX007, indicating potential for major therapeutic advantage.
• Advancement of ANX1502, a novel oral small molecule inhibitor, into clinical trials.

Negatives

• The company reported a net loss of $138.2 million for the year ended December 31, 2024.
• The company has an accumulated deficit of $710.7 million as of December 31, 2024.
• The company has no products approved for commercial sale and has not generated any revenue from sales of its product candidates.

Risks

• The company is dependent on the successful development and regulatory approval of its product candidates.
• Clinical trials may encounter delays or may not be completed on expected timelines.
• Adverse events or undesirable side effects from product candidates could halt development or prevent regulatory approval.
• The company relies on third-party suppliers for manufacturing, and their failure to comply with requirements could affect the business.
• Obtaining adequate coverage and reimbursement for product candidates is crucial for commercial success.
• Collaboration arrangements may not be successful.
• The company may be unable to obtain, maintain, and enforce intellectual property protection.
• The company's stock price has been and could continue to be volatile.
• Failure to comply with data protection laws could lead to penalties and adverse publicity.
• The company may need to raise additional capital, which may not be available on acceptable terms or at all.

Future Outlook

Annexon expects its current capital resources to fund its planned operating expenses into the second half of 2026 and plans to submit a BLA for ANX005 in GBS following a pre-BLA meeting with the FDA in the first half of 2025. The company also expects to complete enrollment of ARCHER II in the second half of 2025 and report topline data in the second half of 2026.

Management Comments

• The company believes that by stopping the classical complement pathway at its start by targeting C1q, their approach may have the potential to provide more complete protection against complement-mediated disorders of the body, brain and eye.
• The company's goal is to suppress excessive or aberrant classical complement activity that contributes to chronic inflammation and tissue damage to slow or even halt disease progression, while preserving the beneficial immune functions of the lectin and alternative complement pathways involved in the clearance of pathogens and damaged cells.

Industry Context

The announcement highlights Annexon's position in the competitive biopharmaceutical industry, specifically within the complement therapeutics space. The company faces competition from established pharmaceutical companies and smaller biotechs developing treatments for GBS, GA, and other autoimmune and neurodegenerative diseases. The document provides an overview of the competitive landscape, including approved therapies and investigational agents in development by companies such as Hansa Biopharma, AstraZeneca/Alexion, Apellis, Astellas, Regeneron, Roche, GSK, and Aurinia.

Comparison to Industry Standards

• The document mentions specific competitors and their programs, such as Apellis's Syfovre and Astellas's Izervay (avacincaptad pegol) which are already FDA-approved for GA, setting a benchmark for Annexon's ANX007.
• The Phase 3 trial results of AstraZeneca/Alexion's SOLIRIS (eculizumab) in GBS, which did not meet its primary endpoint, provide a contrasting example to Annexon's positive Phase 3 results with ANX005.
• The document references Hansa Biopharma's open label Phase 2 trial of imlifidase in GBS, providing a direct comparison to Annexon's ANX005 program.
• The document mentions Regeneron's pozelimab, a C5 inhibiting monoclonal antibody combined with cemdisiran, a C5-targeted siRNA molecule, which is in Phase 3 development for GA, providing a direct comparison to Annexon's ANX007 program.
• The document mentions Sanofi's Enjaymo, which was approved by the FDA for CAD in February 2022, providing a direct comparison to Annexon's ANX1502 program.
• The document mentions GSK's Benlysta and Aurinia's Lupkynis, which are approved medicines specifically for LN, providing a direct comparison to Annexon's ANX009 program.
• The document mentions Biogen's Qalsody, an antisense oligonucleotide that binds to SOD1 mRNA, for those ALS patients with SOD1-ALS, received accelerated approval from the FDA in April 2023, providing a direct comparison to Annexon's ANX005 program.

Stakeholder Impact

• Positive clinical trial results and potential regulatory approvals could benefit patients with GBS and GA.
• Successful commercialization of product candidates could create value for shareholders.
• Continued research and development activities may provide opportunities for employees and consultants.
• Reliance on third-party manufacturers and CROs impacts those stakeholders.

Next Steps

• Prepare for BLA submission for ANX005 in GBS, targeting a pre-BLA meeting with the FDA in the first half of 2025.
• Execute the global registration program for ANX007 in GA, completing enrollment of ARCHER II in the second half of 2025 and reporting topline data in the second half of 2026.
• Advance the first-in-kind oral small molecule program, ANX1502, completing the proof-of-concept study in CAD with data expected in mid-2025.

Key Dates